Interferon-beta inhibits Th17 cell differentiation in patients with multiple sclerosis

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 10, Issue 2, 2010, Pages 161-167

  Ramgolam, Vinod S ^a   Markovic Plese, Silva ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

B cells; Dendritic cells; Innate immune response; Interferon beta; Multiple sclerosis; Th17 cells

Indexed keywords

BETA INTERFERON; CD45RA ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P35; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 27; STAT1 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ARTICLE; B LYMPHOCYTE; CELL DIFFERENTIATION; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; IMMUNOREGULATION; MULTIPLE SCLEROSIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE; TH17 CELL;

EID: 77954041785     PISSN: 18715303     EISSN: None     Source Type: Journal    
DOI: 10.2174/187153010791213029     Document Type: Article

References (75)

1. Hafler, D.A. (2004) Multiple sclerosis. J. Clin. Invest., 113, 788-794.
2. Sospedra, M. and Martin, R. (2005) Immunology of multiple sclerosis. Annu. Rev. Immunol., 23, 683-747.
3. Markovic-Plese, S. and McFarland, H.F. (2001) Immunopatho-genesis of the multiple sclerosis lesion. Curr. Neurol. Neurosci. Rep., 1, 257-262.
4. Muraro, P.A.; Wandinger K.P.; Bielekova B.; Gran, B.; Marques, A.; Utz, U.; McFarland, H.F.; Jacobson, S. and Martin, R. (2003) Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders. Brain, 126, 20-31.
5. The IFNb Multiple Sclerosis Study Group. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I: Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology, 43, 655-661.
6. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Study Group. (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet, 352, 1498-1504.
7. Jacobs, L.D.; Cookfair, D.L.; Rudick, R.A.; Herndon, R.M.; Richert, J.R.; Salazar, A.M.; Fischer, J.S.; Goodkin, D.E.; Granger, C.V.; Simon, J.H.; Alam, J.J.; Bartoszak, D.M.; Bourdette, D.N.; Braiman, J.; Brownscheidle, C.M.; Coats, M.E.; Cohan, S.L.; Dougherty, D.S.; Kinkel, R.P.; Mass, M.K.; Munschauer, F.E.; Priore, R.L.; Pullicino, P.M.; Scherokman, B.J.; Whitham, R.H. and The Multiple Sclerosis Collaborative (MSCRG) Research Group. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol., 39, 285-294.
8. Jacobs, L.D.; Beck, R.W.; Simon, J.H.; Kinkel, R.P.; Brown-scheidle, C.M.; Murray, T.J.; Simonian, N.A.; Slasor, P.J. and Sandrock, A.W. (2000). Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med., 343, 898-904.
9. Kappos, L.; Polman, C.H.; Freedman, M.S.; Edan, G.; Hartung, H.P.; Miller, D.H.; Montalban, X.; Barkhof, F.; Bauer, L.; Jakobs, P.; Pohl, C. and Sandbrink, R. (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology, 67, 1242-1249.
10. Comi, G.; Filippi, M.; Barkhof, F.; Durelli, L.; Edan, G.; Fernandez, O.; Hartung, H.; Seeldrayers, P.; Sorensen, P.S.; Rovaris, M.; Martinelli, V. and Hommes, O.R. (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet, 357, 1576-1582.
11. Wandinger, K.P.; Wessel, K.; Neustock, P.; Siekhaus, A. and Kirchner, H. (1997) Diminished production of type-I interferons and interleukin-2 in patients with multiple sclerosis. J. Neurol. Sci., 149, 87-93.
12. Wandinger, K.P.; Reissland, P.; Kirchner, H.; Wessel, K. and Otto, M. (1998) Production of endogenous interferon-alpha and beta in patients with multiple sclerosis. J. Neurol. Neurosurg. Psychiatry, 64, 277-278.
13. Guo, B.; Chang, E.Y. and Cheng, G. (2008) The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J. Clin. Invest., 118, 1680-1690.
14. Teige, I.; Treschow, A.; Teige, A.; Mattsson, R.; Navikas, V.; Leanderson, T.; Holmdahl, R. and Issazadeh-Navikas, S. (2003) IFN-beta gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis. J. Immunol., 170, 4776-4784.
15. Prinz, M.; Schmidt, H.; Mildner, A.; Knobeloch, K.P.; Hanisch, U.K.; Raasch, J.; Merkler, D.; Detje, C.; Gutcher, I.; Mages, J.; Lang, R.; Martin, R.; Gold, R.; Becher, B.; Brück, W. and Kalinke, U. (2008) Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity, 28, 675-686.
16. Shinohara, M.l.; Kim, J.H.; Garcia, V.A. and Cantor. H. (2008) Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin. Immunity, 29, 68-78.
17. Sturzebecher, S.; Wandinger, K.P.; Rosenwald, A.; Sathyamoorthy, M.; Tzou, A.; Mattar, P.; Frank, J.A.; Staudt, L.; Martin, R. and McFarland, H.F. (2003) Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain, 126, 1419-1429.
18. Stone, L.A.; Frank, J.A.; Albert, P.S.; Bash, C.N.; Calabresi, P.A.; Maloni, H. and McFarland, H.F. (1997) Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure. Neurology, 49, 862-869.
19. Rio, J.; Nos, C.; Tintore, M.; Borras, C.; Galan, I.; Comabella, M. and Montalban, X. (2002) Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. Ann. Neurol., 52, 400-406.
20. Rudick, R.A.; Lee, J.C.; Simon, J.; Ransohoff, R.M. and Fisher, E. (2004) Defining interferon beta response status in multiple sclerosis patients. Ann. Neurol., 56, 548-555.
21. ] Van Baarsen, L.G.; Vosslamber, S.; Tijssen, M.; Baggen, J.M.; Van Der Voort, L.F.; Killestein, J.; Van Der Pouw Kraan, T.C.; Polman, C.G. and Verweij, C.L. (2008) Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS One, 3, E1927.
22. Wandinger, K.P.; Lunemann, J.D.; Wengert, O.; Bellmann-Strobl, J.; Aktas, O.; Weber, A.; Grundstrom, E.; Ehrlich, S.; Wernecke, K.D.; Volk, H.D. and Zipp, F. (2003) TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet, 361, 2036-2043.
23. Comabella, M.; Lunemann, J.D.; Rio, J.; Sanchez, A.; Lopez, C.; Julia, E.; Fernandez, M.; Nonell, L.; Camina-Tato, M.; Deisenhammer, F.; Caballero, E.; Tortola, M.T.; Prinz, M.; Montalban, X. and Martin, R. (2009) A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain, 132, 3353-3365.
24. Byrnes, A.A.; Mcarthur, J.C. and Karp, C.L. (2002) Interferon-beta therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production. Ann. Neurol., 51, 165-174.
25. Wandinger, K.P.; Sturzebecher, C.S.; Bielekova, B.; Detore, G.; Rosenwald, A.; Staudt, L.M.; McFarland, H.F. and Martin, R. (2001) Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann. Neurol., 50, 349-57.
26. Harrington, L.E.; Hatton, R.D.; Mangan, P.R.; Turner, H.; Murphy, T.L.; Murphy, K.M. and Weaver, C.T. (2005) Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol., 6,1123-1132.
27. Batten, M.; Li, J.; Yi, S.; Kljavin, N.M.; Danilenko, D.M.; Lucas, S.; Lee, J.; De Sauvage, F.J. and Ghilardi, N. (2006) Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat. Immunol., 7, 929-936.
28. Acosta-Rodriguez, E.V.; Napolitani, G.; Lanzavecchia, A. and Sallusto, F. (2007) Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol., 8, 942-949.
29. Wilson, N.J.; Boniface, K.; Chan, J.R.; Mckenzie, B.S.; Blumenschein, W.M.; Mattson, J.D.; Basham, B.; Smith, K.; Chen, T.; Morel, F.; Lecron, J.C.; Kastelein, R.A.; Cua, D.J.; Mcclanaha, T.K.; Bowman, E.P. and De Waal Malefyt, R. (2007) Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol., 8, 950-957.
30. Annunziato, F.; Cosmi, L.; Santarlasci, V.; Maggi, L.; Liotta, F.; Mazzinghi, B.; Parente, E.; Fili, L.; Ferri, S.; Frosali, F.; Giudici, F.; Romagnani, P.; Parronchi, P.; Tonelli, F.; Maggi, E. and Romagnani S. (2007) Phenotypic and functional features of human Th-17 cells. J. Exp. Med., 204, 1849-1861.
31. Yang, L.; Anderson, D.E.; Baecher-Allan, C.; Hastings, W.D.; Bettelli, E.; Oukka, M.; Kuchroo, V.K. and Hafler, D.A. (2008) IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature, 454, 350-352.
32. Volpe, E.; Servant, N.; Zollinger, R.; Bogiatzi, S.I.; Hupé, P.; Barillot, E. and Soumelis, V. (2008) Nat. Immunol., 9, 650-657.
33. Manel, N.; Unutmaz, D. and. Littman, D.R. (2008) The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat. Immunol., 9, 641-649.
34. Acosta-Rodriguez, E.V.; Rivino, L.; Geginat, J.; Jarrossay, D.; Gattorno, M.; Lanzavecchia, A.; Sallusto, F. and Napolitani, G. (2007) Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat. Immunol., 8, 639-646.
35. Lee, Y.K.; Turner, H.; Maynard, C.L.; Oliver, J.R.; Chen, D.; Elson, C.O. and Weaver, C.T. (2009) Late developmental plasticity in the T helper 17 lineage. Immunity, 30, 92-107.
36. Carlson, T.; Kroenke, M.; Rao, P.; Lane, T.E. and Segal, B. (2008) The Th17-ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune disease. J. Exp. Med., 205, 811-823.
37. Kotake, S.; Udagawa, N.; Takahashi, N.; Matsuzaki, K.; Itoh, K.; Ishiyama, S.; Saito, S.; Inoue, K.; Kamatani, N.; Gillespie, M.T.; Martin, T.J. and Suda, T. (1999) IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest., 103, 1345-1352.
38. Fitch, E.; Harper, E.; Skorcheva, I.; Kurtz, S.E. and Blauvelt, A. (2007) Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr. Rheumatol. Rep., 9, 461-467.
39. Amadi-Obi, A.; Yu, C.R.; Liu, X.; Mahdi, R.M.; Clarke, G.L.; Nussenblatt, R.B.; Gery, I.; Lee, Y.S. and Egwuagu, C.E. (2007) Th-17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT-1. Nat. Med., 13, 711-718.
40. Matusevicius, D.; Kivisakk, P.; He, B.; Kostulas, N.; Ozenci, V.; Fredrikson, S. and Link, H. (1999). Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult. Scler., 5, 101-104.
41. Durelli, L.; Conti, L.; Clerico, M.; Boselli, D.; Contessa, G.; Ripellino, P.; Ferrero, B.; Eid, P. and Novelli, F. (2009) T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann. Neurol., 65, 499-509.
42. Lock, C.; Hermans, G.; Pedotti, R.; Brendolan, A.; Schadt, E.; Garren, H.; Langer-Gould, A.; Strober, S.; Cannella, B.; Allard, J.; Klonowski, P.; Austin, A.; Lad, N.; Kaminski, N.; Galli, S.J.; Oksenberg, J.R.; Raine, C.S.; Heller, R. and Steinman, L. (2002) Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med., 8, 451-453.
43. Tzartos, J.S.; Friese, M.A.; Craner, M.J.; Palace, J.; Newcombe, J.; Esiri, M. M. and Fugger, L. (2008) Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol., 172, 146-55.
44. Zhang, X.; Tang, Y.; Sujkowska, D.; Wang, J.; Ramgolam, V.S.; Sospedra, M.; Adams, J.; Martin, R.; Pinilla, C. and Markovic-Plese, S. (2008) Degenerate TCR recognition and dual DR2 restriction in auto-reactive T-cells: implications for the initiation of the autoimmune response in multiple sclerosis Eur. J. Immunol., 38, 1297-1309.
45. Devergne, O.; Hummel, M.; Koeppen, H.; Le Beau, M.M.; Nathanson, E.C.; Kieff, E. and Birkenbach, M. (1996) A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. J. Virol., 70, 1143-1153.
46. Pflanz, S.; Timans, J.C.; Cheung, J.; Rosales, R.; Kanzler, H.; Gilbert, J.; Hibbert, L.; Churakova, T.; Travis, M.; Vaisberg, E.; Blumenschein, W.M.; Mattson, J.D.; Wagner, J.l.; To, W.; Zurawski, S.; McClanahan, T.K.; Gorman, D.M.; Bazan, J.F.; de Waal Malefyt, R.; Rennick, D. and Kastelein, R.A. (2002) IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity, 16, 779-790.
47. Pflanz, S.; Hibbert, L.; Mattson, J.; Rosales, R.; Vaisberg, E.; Bazan, J.F.; Phillips, J.H., McClanahan, T.K.; De Waal Malefyt, R. and Kastelein, R.A. (2004) WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J. Immunol., 172, 2225-2231.
48. Ramgolam, V.S.; Sha, Y.; Jin, J.; Zhang, X. and Markovic-Plese, S, (2009) IFN-beta inhibits human Th17 cell differentiation. J. Immunol., 183, 5418-5427.
49. Parham, C.; Chirica, M.; Timans, J.; Vaisberg, E.; Travis, M.; Cheung, J.; Pflanz, S.; Zhang, R.; Singh, K.P.; Vega, F.; To, W.; Wagner, J.; O'Farell, A.M.; McClanahan, T.; Zurawski, S.; Hannum, C.; Gorman, D.; Rennick, D.M.; Kastelein, R.A.; de Waal Malefyt, R. and Moore, K.W. (2002) A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J. Immunol., 168, 5699-5708.
50. Chen, Y.; Langrish, C.L.; Mckenzie, B.; Joyce-Shaikh, B.; Stumhofer, J.S.; Mcclanahan, T.; Blumenschein, W.; Churakovsa, T.; Low, J.; Presta, L.; Hunter, C.A.; Kastelein, R.A. and Cua, J.D. (2006) Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J. Clin. Invest., 116, 1317-1326.
51. Cua, D.J.; Sherlock, J.; Chen, Y.; Murphy, C.A.; Joyce, B.; Seymour, B.; Lucian, L.; To, W.; Kwan, S.; Churakova, T.; Zurawski, S.; Wiekowski, M.; Lira, S.A.; Gorman, D.; Kastelein, R.A. and Sedgwick, J.D. (2003) Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature, 421, 744-748.
52. Zhang, G.X.; Yu, S.; Gran, B.; Li, J.; Siglienti, I.; Chen, X.; Calida, D.; Ventura, E.; Kamoun, M. and Rostami, A. (2003) Induction of experimental autoimmune encephalomyelitis in IL-12 receptor-beta 2-deficient mice:12-responsiveness is not required in the pathogenesis of inflammatory demyelination in the central nervous system. J. Immunol., 171, 4485-4492.
53. Gautier, G.; Humbert, M.; Deavieau, F.; Scuiller, M.; Hiscott, J.; Bates, E.E.; Trinchieri, G.; Caux, G. and Garrone, P. (2005) A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J. Exp. Med., 201, 1435-1446.
54. Chen, Z.; Tato, C.M.; Muul, L.; Laurence, A. and O'Shea, J.J. (2007) Distinct regulation of interleukin-17 in human T helper lymphocytes. Arthritis Rheum., 56, 2936-2946.
55. Lee, W.W.; Kang, S.W.; Choi, J.; Lee, S.H.; Shah, K.; Eynon, E.E.; Flavell, R.A. and Kang I. (2009) Regulating human Th17 cells via differential expression of IL-1 receptor. Blood, 115, 530-540.
56. Vaknin-Dembinsky A.; Balashov, K. and Weiner, H.L. (2006) IL-23 is increased in dendritic cells in multiple scelerosis and downregulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J. Immunol., 176, 7768-7774.
57. Li, Y.; Chu, N.; Hu, A.; Gran, B.; Rostami, A. and Zhang, G.X. (2007) Increased IL-23p19 expression in multiple sclerosis lesions and its induction in microglia. Brain, 130, 490-501.
58. Zhang, X.; Jin, J.; Tang, Y.; Speer, D.; Sujkowska, D. and Markovic-Plese, S. (2009) IFN-beta1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation. J. Immunol., 182, 3928-3936.
59. Krakauer, M.; Sorensen, P.; Khademi, M.; Olsson, T. and Sellebjerg, F. (2008) Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression. Mult. Scler., 14, 622-630.
60. Coclet-Ninin, J.; Dayer, J.M. and Burger, D. (1997) Interferon-beta not only inhibits interleukin-1beta and tumor necrosis factor-alpha but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells. Eur. Cytokine. Netw., 8, 345-349.
61. Wong, P.K.; Croker, B.A.; O'donnell, K.; Sims, N.A.; Drake, S.; Kiu, H.; Mcmanus, E.J.; Alexander, W.S.; Roberts, A.W. and Wicks, I.P. (2006) SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis. J. Clin. Invest., 116, 1571-1581.
62. Frobose, H.; Ronn, S.G.; Heding, P.E.; Mendoza, H.; Cohen, P.; Mandrup-Poulsen, T. and Billestrup, N. (2006) Suppressor of cytokine signaling-3 inhibits interleukin-1 signaling by targeting the TRAF-6/TAK1 complex. Mol. Endocrinol., 20, 1587-1596.
63. Li, Y.; Chu, N.; Rostami, A. and Zhang, G.X. (2006) Dendritic cells transduced with SOCS-3 exhibit a tolerogenic/DC2 phenotype that directs type 2 Th cell differentiation in vitro and in vivo. J. Immunol., 177, 1679-1688.
64. Zhang, X.; Jin, J.; Peng, X.; Ramgolam, V.S. and Markovic-Plese, S. (2008) Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORc in CD4+ lymphocytes. J. Immunol., 180, 6988-6996.
65. Tanaka, K.; Ichiyama, K.; Hashimoto, M.; Yoshida, H.; Takimoto, T.; Takaesu, G.; Torisu, T.; Hanada, T.; Yasukawa, H.; Fukuyama, S.; Inoue, H.; Nakanishi, Y.; Kobayashi, T. and Yoshimura, A. (2008) Loss of suppressor of cytokine signaling 1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFN-gamma on STAT3 and Smads. J. Immunol., 180, 3746-3756.
66. Ma, C,S.; Chew, Gy.; Simpson, N.; Priyadarshi, A.; Wong, M.; Grimbacher, B.; Fulcher, D.A.; Tangye, S.G. and Cook, M.C. (2008) Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J. Exp. Med., 205, 1551-1557.
67. Diveu, C.; Mcgeachy, M.J.; Boniface, K.; Stumhofer, J.S.; Sathe, M.; Joyce-Shaikh, B.; Chen, Y.; Tato, C.M.; McClanahan, T.K.; De Waal Malefyt, R.; Hunter, C.A.; Cua, D.J. and Kastelein, R.A. (2009) IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. J. Immunol., 182, 5748-5756.
68. Chen, Z.; Laurence, A.; Kanno, Y.; Pacher-Zavisin, M.; Zhu, B.M.; Tato, C.; Yoshimura, A.; Hennighausen, L. and O'Shea, J.J. (2006)Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc. Natl. Acad. Sci. USA, 103, 8137-8142.
69. Van Boxel-Dezaire, A.H.; Hoff, S.C.; Van Oosten, B.W.; Verweij, C.l.; Drager, A.M.; Ader, H.J.; Van Houwelingen, J.C.; Barkhof, F.; Polman, C.H. and Nagelkerken, L. (1999) Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann. Neurol., 45, 695-703.
70. Bartosik-Psujek, H. and Stelmasiak, Z. (2006) The interleukin-10 levels as a potential indicator of positive response to interferon beta treatment of multiple sclerosis patients. Clin. Neurol. Neurosurg., 108, 644-647.
71. Ozenci, V.; Kouwenhoven, M.; Huang, Y.M.; Xiao, B.; Kivisakk, P.; Fredrikson, S. and Link, H. (1999) Multiple sclerosis: levels of interleukin-10-secreting blood mononuclear cells are low in untreated patients but augmented during interferon-beta-1b treatment. Scand. J. Immunol., 49, 554-561.
72. Matsushita, T.; Yanaba, K.; Bouaziz, J.D.; Fujimoto, M. and Tedder, T.F. (2008) Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest., 118, 3420-3430.
73. Fitzgerald, D.C, Ciric, B.; Touil, T.; Harle, H.; Grammatikopolou, J.; Das Sarma, J.; Gran, B.; Zhang, G.X. and Rostami, A. (2007) Suppressive effect of IL-27 on encephalitogenic Th17 cells and the effector phase of experimental autoimmune encephalomyelitis. J. Immunol., 179, 3268-3275.
74. Stumhofer, J.S.; Silver, J.S.; Laurence, A.; Porrett, P.M.; Turka, T.H.; Ernst, M.;.Saris, S.J.; O'Shea, J.J. and Hunter, C.A. (2007) Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat. Immunol., 8, 1363-1371.
75. Sun, C.M.; Deriaud, E.; Leclerc, C. and Lo-Man, R. (2005) Upon TLR9 signaling, CD5+ B cells control the IL-12-dependent Th1-priming capacity of neonatal DCs. Immunity, 22, 467-477.